A recent study conducted by the Guangzhou Institutes of Biomedicine and Health (GIBH) of the Chinese Academy of Sciences (CAS ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

1Department of Biotechnology, Indian Institute of Technology Madras (IIT Madras), Chennai, India.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...